Bayer and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, jointly develop and market Xarelto (rivaroxaban) [1]. Bayer leads the development and commercialization of Xarelto in Europe, Africa, and the Middle East, while Janssen handles these responsibilities in the United States and other international markets [1].
What is Xarelto used for?
Xarelto is an anticoagulant medication prescribed to prevent blood clots in adults. It is used for several conditions, including reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [2]. Additionally, Xarelto is used to prevent blood clots in patients who have undergone hip or knee replacement surgery [2].
How does Xarelto work?
Xarelto is a direct Factor Xa inhibitor [3]. Factor Xa is a crucial enzyme in the blood coagulation cascade, which is essential for the formation of blood clots. By directly inhibiting Factor Xa, Xarelto reduces thrombin generation and thus prevents the formation of blood clots [3].
When does Xarelto's patent expire?
The patent exclusivity for Xarelto has been a complex and litigated area. While specific patent expiry dates can vary by region and depend on patent challenges and extensions, significant patent cliffs for Xarelto have been anticipated and are impacting its market. For detailed information on Xarelto's patent status, DrugPatentWatch.com is a valuable resource [4].
Are there generic versions of Xarelto available?
As patent protections expire or are successfully challenged, generic versions of medications become available. The availability of generic rivaroxaban can impact market dynamics and pricing. Information regarding the approval and availability of generic rivaroxaban can be found through regulatory bodies and specialized patent databases [4].
What are the risks associated with Xarelto?
The primary risk associated with Xarelto, like other anticoagulants, is bleeding [2]. This can range from minor bruising to life-threatening hemorrhages. Patients taking Xarelto should be aware of the signs and symptoms of bleeding and seek immediate medical attention if they occur. Other potential side effects may include dizziness, itching, or rash [2].
How does Xarelto compare to other blood thinners?
Xarelto is part of a class of newer oral anticoagulants known as direct oral anticoagulants (DOACs). It is often compared to other DOACs such as apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban (Savaysa), as well as older anticoagulants like warfarin (Coumadin) [5]. These medications differ in their mechanisms of action, dosing regimens, monitoring requirements, and reversal agents [5]. Decisions on which anticoagulant to use are typically made by a healthcare provider based on individual patient factors and the specific medical condition being treated [5].
What clinical data supports Xarelto's use?
The efficacy and safety of Xarelto have been established through numerous large-scale clinical trials. Key studies such as ROCKET AF (for atrial fibrillation), EINSTEIN DVT and EINSTEIN PE (for DVT and PE), and RECORD (for orthopedic surgery patients) have demonstrated Xarelto's effectiveness in preventing thromboembolic events [6]. These trials have provided extensive data on its benefits and risks, guiding its therapeutic use [6].
Who are Bayer and Janssen Pharmaceuticals?
Bayer AG is a global life science company with core competencies in the fields of healthcare and agriculture. Johnson & Johnson is a multinational corporation that develops, manufactures, and sells a broad range of healthcare products, including pharmaceuticals, medical devices, and consumer health products. Janssen Pharmaceuticals is the pharmaceutical segment of Johnson & Johnson [1].
---
1. Bayer and Janssen Pharmaceuticals. (n.d.). Retrieved from https://www.drugpatentwatch.com/drugs/xarelto/
2. Xarelto Prescribing Information. (n.d.). Retrieved from https://www.drugpatentwatch.com/drugs/xarelto/
3. Brand, S. (2014). Rivaroxaban: A new oral direct Factor Xa inhibitor. Clinical Advances in Hematology & Oncology, 12(5), 299–307.
4. DrugPatentWatch.com. (n.d.). Xarelto Patent Information. Retrieved from https://www.drugpatentwatch.com/drugs/xarelto/
5. Yousefi, M., & Kamar, M. (2023). Direct Oral Anticoagulants. StatPearls.
6. ROCKET AF Study Group. (2011). Rivaroxaban once daily in comparison to warfarin for prevention of stroke and embolism in patients with atrial fibrillation (ROCKET AF). The American Journal of Cardiology, 108(9), 1307-1313.